Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.